Qiagen inks companion Dx deal for Lilly's blood cancer drug
This article was originally published in Clinica
Qiagen has struck a companion diagnostic partnership with yet another pharma heavyweight, the second deal of its kind in as many months. The firm has agreed to develop a test for use with Lilly’s investigational JAK2 inhibitor, which is currently in Phase I. The drug targets the Janus kinase 2 (JAK2) gene, which has been shown to play a role in myeloproliferative neoplasms, a variety of blood cancers that cause blood cells to grow abnormally. Financial terms of the deal were not disclosed.